GlassScriptPhysician profile
Dhananjay Chatterjee
NPI 1497117782
$74,156.77
in general payments reported to CMS, 2019-2025
17 companies · $52K in 2025
The $52K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $1,518 · 2023: $2,242 · 2024: $19K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,120 · Travel and Lodging: $4,651 · Grant: $125 · Debt Forgiveness: $32.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,775.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,300.00 |
| Food and Beverage | $11,491.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,120.00 |
| Travel and Lodging | $4,650.71 |
| Grant | $125.00 |
| Debt Forgiveness | $32.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $58,197.76 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Nipro Medical Corporation | $6,120.00 | 2025 | Makoto |
| Abbott Laboratories | $3,004.81 | 2022-2025 | Optis, Dragonfly Opstar, Pressurewire |
| Abiomed | $2,642.43 | 2023-2025 | Impella |
| Heartflow, INC. | $1,236.95 | 2024-2025 | |
| Medtronic, INC. | $1,119.47 | 2021-2025 | Onyx Frontier |
| Boston Scientific Corporation | $1,095.51 | 2022-2025 | Emerge Push, Avvigo Guidance System, General - Balloon Catheters |
| Esperion Therapeutics, INC. | $124.72 | 2023 | Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $123.03 | 2024 | Xarelto |
| Madrigal Pharmaceuticals | $97.73 | 2024 | Resmetirom |
| Philips North America LLC | $92.30 | 2022 | |
| Cardiva Medical, INC. | $87.10 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Penumbra, INC. | $63.06 | 2023 | Indigo System |
| Baxter Healthcare | $32.58 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $18.09 | 2023 | Diamondback Coronary |
| Cordis US Corp. | $17.11 | 2025 | Selution Slr Ptca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhananjay Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.